Oric Pharmaceuticals, Inc. — Director's Dealing 2021

May 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-05-14

Reporting Person: Chacko Jacob (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-14	Common Stock	S	13896	$25.3645	Disposed	44284	Direct
2021-05-17	Common Stock	S	2550	$25.0526	Disposed	41734	Direct
2021-05-18	Common Stock	S	11132	$25.3708	Disposed	30602	Direct
2021-05-18	Common Stock	S	200	$26.03	Disposed	30402	Direct

Footnotes

F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Represents the weighted average share price of an aggregate total of 13,896 shares sold in the price range of $25.00 to $25.85 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average share price of an aggregate total of 2,550 shares sold in the price range of $25.00 to $25.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average share price of an aggregate total of 11,132 shares sold in the price range of $25.00 to $25.93 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.